Global Bleeding Disorders Treatment Market, “By Product Type (Hemophilia A, Hemophilia B, and Von Willebrand Disease), By Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Anti-fibrinolytics, Fibrin Sealant), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast is projected to reach USD 41.94 billion by 2025, at a CAGR of 14.5% during the forecast period of 2018 to 2025.
Click Here For Free Sample Report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-bleeding-disorders-treatment-market
Global Bleeding Disorders Treatment Market
Bleeding disorder is a medical condition in which blood clotting process called as coagulation gets hampered. In normal cases when we are injured, our blood normally begins to clot to prevent extensive loss of blood but in certain conditions coagulating of blood don’t occur, which results in heavy or prolonged bleeding, this condition is common in hemophilia A&B. Bleeding disorders can cause abnormal bleeding both outside and inside of the body. There are three main types of this condition: hemophilia, clotting factor deficiency, and Von Willebrand Disease.
According to the national hemophilia foundation, in April 2015, Emergent BioSolutions Inc. recieved the approval from the U.S. Food and Drug Administration for IXINITY [coagulation factor IX (recombinant)], which is an intravenous recombinant human coagulation factor IX therapeutic for the control and prevention of bleeding episodes and for perioperative management in adults and children with Hemophilia B.
According to a news released by catalyst biosciences in May 2018, Catalyst Biosciences provided an update on the Company’s ongoing clinical development work with CB 2679d, which is a next-generation subcutaneous Factor IX for the treatment of hemophilia B. CB 2679d is currently in Phase 1/2 clinical trials and was awarded orphan drug designations by the European Commission in June 2017 and by the U.S. Food and Drug Administration in September 2017.
For Customized Reports and Discounts, Mail us @ email@example.com
Market Segmentation: Global Bleeding Disorders Treatment Market
The global market for bleeding disorder treatment by the following sub-categories is presented
By Product Type
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
By Drug Class
- Plasma Derived Coagulation Factor Concentrates
- Recombinant Coagulation Factor Concentrates
- Fibrin Sealant
- North America
- South America
- Middle East and Africa
Order a Copy of Global Bleeding Disorders Treatment Market Report @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bleeding-disorders-treatment-market
FACTORS DRIVING GROWTH IN GLOBAL BLEEDING DISORDERS TREATMENT MARKET
The increasing prevalence of bleeding disorders:
According to an article by national hemophilia foundation 2016, the rate of occurrence of hemophilia A is 1 in 5000 live male birth. It is estimated that around 20,000 people are suffering from hemophilia in United States. The worldwide incidence of hemophilia is not well known but it is estimated that more than 400,000 peoples are suffering from hemophilia A worldwide, out of which around 75.0% of the people suffering from hemophilia A receives inadequate treatment or has no access to treatment.
Von Willebrand disease is a genetic disorder in which the blood does not clot properly. It is caused by a deficient or defective blood protein, von Willebrand factor. This is the most common bleeding disorder, and it was found that around 1.0% of total population of U.S. is suffering from this disorder.
According to Statista, number of people diagnosed from the bleeding disorder in 2016 was around 184,723 people with hemophilia, 71,648 suffering from Von willebrand disease and 39,495 suffering from other bleeding disorders.
According to Statista, age factor plays an important role in hemophilia B, it was found that between the age group of 0-4 years 9.0% of Americans suffer from hemophilia B, between age group 5-13 years around 24.0% of Americans suffer from Hemophilia B, 11.0% of people have hemophilia B between the age group 14-18 years, 29.0% between 19-44 years, 26.0% above 456 years.
And according to the centers for disease control and prevention statistics, in the U.S. around 400 newborns suffer from hemophilia every year.
In other ways we can also assume that with the increase in population the chances for the increase in hemophilia cases will also increase, as this is a genetic disorder there are more chances of infants or children getting affected by this disorder through their parents, hence this market is expected is to achieve a stable growth in future.
Rising Awareness Regarding Bleeding Disorders:
Every year on April 17, World Hemophilia Day is celebrated around the world in order to increase awareness of hemophilia and other inherited bleeding disorders. According to an article by Deccan chronicle regarding hemophilia day, The Kerala government has lifted a lifetime ceiling of Rs. 3, 00,000/- for treatment of acute bleeds. For those holding Karunya cards, the coverage is unlimited for on demand treatment and next year the government is embarking on prophylaxis (regular replacement therapy) for children under five years.
A comprehensive haemophilia care centre in Aluva in Kerala, it was found that Out of 851 patients on its rolls, 619 suffer from haemophilia A, 131 from haemophilia B and 101 from other bleeding disorders. In the short span of just four years this center has publishes 7 international publications. This center plans a medical camp with various facilities and factors & inhibitor assay.
On 17 April 2016 that is on hemophilia day, Roche joined the global haemophilia community to increase awareness and increase support for those living who are suffering with this bleeding disorder. And the theme for this year was, ‘treatment for all is the vision of all’, focuses on overcoming the lack of adequate treatment that the majority of people with bleeding disorders still face.
Hence with the increase in awareness regarding hemophilia by government as well by private organization, the global bleeding disorder market is expected to achieve a stable platform in future.
Some of the major competitor in this market are Shire, CSL, Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen, Octapharma, Grifols, Kiadis Pharma, Bellicum Pharmaceuticals, Inc, Baxalta, Alnylam Pharmaceuticals, Inc, Emergent BioSolutions, Catalyst Biosciences, Xencor, Xenetic Biosciences, Inc., Bristol-Myers Squibb Company, Sanofi, Amgen Inc, Bioverativ, Janssen Global Services, LLC, Dimension Therapeutics, Inc. among others.
This Report Consists of:
• No of pages: 350
• No of Figures: 60
• No of Tables: 220
Frequently Asked Questions:
• What will the market size be in 2025?
• What are the key factors driving the global market?
• What are the challenges to market growth?
• Who are the key players in the market?
• What are the market opportunities and threats faced by the key players?
• What will be the growth rate in 2025?
• Which strategies are used by top players in the Global Bleeding Disorders Treatment Market?
Request For TOC Here @ https://databridgemarketresearch.com/toc/?dbmr=global-bleeding-disorders-treatment-market
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research
Company Name: Data Bridge Market Research Private Limited
Contact Person: Sopan Gedam
Email: Send Email
Address:Office Number 402, Amanora Chambers, Magarpatta Road, Hadapsar